Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 pivotal trial assessing pegsitacianine

Trial Profile

A phase 3 pivotal trial assessing pegsitacianine

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegsitacianine (Primary)
  • Indications Solid tumours
  • Focus Diagnostic use; Registrational
  • Sponsors OncoNano Medicine

Most Recent Events

  • 25 Oct 2021 According to OncoNano Medicine media release, the Cancer Prevention and Research Institute of Texas (CPRIT) will convert $18.4 million in grant award funding into an equity investment in OncoNano. Proceeds of the financing will be used to support this trial
  • 24 Jun 2021 New trial record
  • 17 Jun 2021 According to OncoNano Medicine media release, the company plans to initiate this trial and submit an IND for this first therapeutic development program in 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top